HRP20040507A2 - Substituted 4-phenyltetrahydroisoquinoline methods - Google Patents

Substituted 4-phenyltetrahydroisoquinoline methods

Info

Publication number
HRP20040507A2
HRP20040507A2 HR20040507A HRP20040507A HRP20040507A2 HR P20040507 A2 HRP20040507 A2 HR P20040507A2 HR 20040507 A HR20040507 A HR 20040507A HR P20040507 A HRP20040507 A HR P20040507A HR P20040507 A2 HRP20040507 A2 HR P20040507A2
Authority
HR
Croatia
Prior art keywords
methyl
dichloro
phenyl
tetrahydroisoquinolin
tetrahydro
Prior art date
Application number
HR20040507A
Other languages
English (en)
Croatian (hr)
Inventor
Hofmeister Armin
Heinelt Uwe
Jochen Lang Hans
Bleich Markus
Wirth Klaus
Gekle Michael
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of HRP20040507A2 publication Critical patent/HRP20040507A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
HR20040507A 2001-12-05 2004-06-04 Substituted 4-phenyltetrahydroisoquinoline methods HRP20040507A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159714 2001-12-05
PCT/EP2002/012990 WO2003048129A1 (fr) 2001-12-05 2002-11-20 4-phenyltetrahydroisoquinoleine, son procede de production, son utilisation comme medicament, et medicament la contenant

Publications (1)

Publication Number Publication Date
HRP20040507A2 true HRP20040507A2 (en) 2005-08-31

Family

ID=7708117

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040507A HRP20040507A2 (en) 2001-12-05 2004-06-04 Substituted 4-phenyltetrahydroisoquinoline methods

Country Status (34)

Country Link
EP (1) EP1453810B1 (fr)
JP (1) JP4510457B2 (fr)
KR (1) KR20050044724A (fr)
CN (1) CN100497314C (fr)
AR (1) AR037620A1 (fr)
AT (1) ATE425968T1 (fr)
AU (1) AU2002356689B2 (fr)
BR (1) BR0214753A (fr)
CA (1) CA2469385A1 (fr)
CO (1) CO5580748A2 (fr)
DE (1) DE50213372D1 (fr)
DK (1) DK1453810T3 (fr)
EC (1) ECSP045138A (fr)
ES (1) ES2324528T3 (fr)
HK (1) HK1072597A1 (fr)
HR (1) HRP20040507A2 (fr)
HU (1) HUP0600854A2 (fr)
IL (1) IL162316A0 (fr)
MA (1) MA27147A1 (fr)
MX (1) MXPA04005343A (fr)
MY (1) MY157371A (fr)
NO (1) NO326650B1 (fr)
NZ (1) NZ533322A (fr)
OA (1) OA12740A (fr)
PE (1) PE20030726A1 (fr)
PL (1) PL369313A1 (fr)
PT (1) PT1453810E (fr)
RS (1) RS48004A (fr)
RU (1) RU2298003C2 (fr)
TN (1) TNSN04100A1 (fr)
TW (1) TWI281860B (fr)
UA (1) UA77042C2 (fr)
WO (1) WO2003048129A1 (fr)
ZA (1) ZA200403711B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
KR101422432B1 (ko) 2005-02-18 2014-07-22 아스트라제네카 아베 항균성 피페리딘 유도체
JP2008531671A (ja) * 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ 化合物
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102006012545A1 (de) * 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (fr) * 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
ES2657938T3 (es) * 2008-12-31 2018-03-07 Ardelyx, Inc. Compuestos y métodos para inhibir el antipuerto mediado por NHE en el tratamiento de trastornos asociados a la retención de líquidos o a la sobrecarga de sales y trastornos del tracto gastrointestinal
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
RU2684097C2 (ru) * 2012-08-21 2019-04-04 Эрделикс, Инк. Соединения и способы для ингибирования NHE-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой, и заболеваний желудочно-кишечного тракта
EP2983667B1 (fr) 2013-04-12 2019-03-20 Ardelyx, Inc. Composés de liaison à nhe3 et procédés d'inhibition du transport de phosphate
CN103788084A (zh) * 2014-03-02 2014-05-14 湖南华腾制药有限公司 四氢异喹啉衍生物及其合成方法
EP3173408B1 (fr) 2014-07-25 2018-11-21 Taisho Pharmaceutical Co., Ltd. Composé phényl tétrahydroisoquinoléine substitué par un hétéroaryle
JP6903923B2 (ja) * 2016-01-22 2021-07-14 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬
MA47203A (fr) 2017-01-09 2019-11-13 Ardelyx Inc Inhibiteurs d'antiport à médiation par nhe
MX2019008170A (es) * 2017-01-09 2020-02-07 Ardelyx Inc Compuestos útiles para tratar transtornos del tracto gastrointestinal.
US20240082406A1 (en) * 2020-12-18 2024-03-14 Shanghai Jemincare Pharmaceutical Co., Ltd Benzoheterocycle substituted tetrahydroisoquinoline compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
KR20080065707A (ko) * 1999-11-03 2008-07-14 에이엠알 테크놀로지, 인크. 4-페닐-치환 테트라히드로이소퀴놀린, 및 노르에피네프린과도파민과 세로토닌의 재흡수를 차단하기 위한 이의 용도
MXPA02004330A (es) * 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
EP1113007A1 (fr) * 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren

Also Published As

Publication number Publication date
HK1072597A1 (en) 2005-09-02
CA2469385A1 (fr) 2003-06-12
ES2324528T3 (es) 2009-08-10
NO326650B1 (no) 2009-01-26
BR0214753A (pt) 2004-12-14
JP4510457B2 (ja) 2010-07-21
AU2002356689B2 (en) 2008-05-15
CN100497314C (zh) 2009-06-10
TWI281860B (en) 2007-06-01
UA77042C2 (en) 2006-10-16
OA12740A (en) 2006-06-30
PL369313A1 (en) 2005-04-18
MXPA04005343A (es) 2004-09-27
IL162316A0 (en) 2005-11-20
EP1453810A1 (fr) 2004-09-08
PE20030726A1 (es) 2003-09-30
WO2003048129A1 (fr) 2003-06-12
PT1453810E (pt) 2009-05-27
RU2298003C2 (ru) 2007-04-27
HUP0600854A2 (en) 2007-02-28
DK1453810T3 (da) 2009-07-20
EP1453810B1 (fr) 2009-03-18
AU2002356689A1 (en) 2003-06-17
AR037620A1 (es) 2004-11-17
TNSN04100A1 (en) 2006-06-01
KR20050044724A (ko) 2005-05-12
MA27147A1 (fr) 2005-01-03
MY157371A (en) 2016-06-15
RU2004120295A (ru) 2006-01-10
NZ533322A (en) 2006-02-24
CN1617856A (zh) 2005-05-18
ATE425968T1 (de) 2009-04-15
TW200306190A (en) 2003-11-16
ZA200403711B (en) 2005-06-09
NO20042158L (no) 2004-08-27
DE50213372D1 (de) 2009-04-30
JP2005515205A (ja) 2005-05-26
CO5580748A2 (es) 2005-11-30
RS48004A (en) 2006-10-27
ECSP045138A (es) 2004-08-27

Similar Documents

Publication Publication Date Title
HRP20040507A2 (en) Substituted 4-phenyltetrahydroisoquinoline methods
US6911453B2 (en) Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
EP1794128B1 (fr) 4-phenyltetrahydro-isoquinolines substituees, procede permettant de les produire, leur utilisation comme medicament et medicament les contenant
EP1838315B1 (fr) 4-phenyltétrahydroisochinolines substituées, procédé pour les préparer, leur utilisation en tant que médicament et médicament les contenant
US6703405B2 (en) Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
EP1613600A1 (fr) 4-phenyltetrahydroisoquinoleine substituee, son procede de fabrication, son utilisation comme medicament, et medicament contenant ce compose
EP1465870B1 (fr) Sels de 4-phenyltetrahydroisochinolinium substitues, procede de fabrication, utilisation en tant que medicament, et medicament contenant ces sels
RU2315766C2 (ru) Замещенные тиофены, их применение в качестве лекарственного или диагностического средства и содержащее их лекарственное средство
HRP980527A2 (en) Sulfonamid-substituted chromans, process for their preparation, their use as medicine, and pharmaceutical preparation containing them

Legal Events

Date Code Title Description
A1OB Publication of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, DE

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081117

Year of fee payment: 7

OBST Application withdrawn